Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NR0B2 | Q15466 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988985 | 0.83 | P2RX7 (0.40) | — | |
| SCHEMBL4522841 | 0.80 | PTPN11 (0.39) | L3MBTL1PTPN11POLBNR0B2ALDH1A1 | |
| SCHEMBL4522833 | 0.80 | PTPN11 (0.39) | L3MBTL1PTPN11POLBNR0B2ALDH1A1 | |
| SCHEMBL4519361 | 0.76 | HSD11B1 (0.49) | L3MBTL1PTPN11POLBNR0B2ALDH1A1 | |
| SCHEMBL4519356 | 0.76 | HSD11B1 (0.49) | L3MBTL1PTPN11POLBNR0B2ALDH1A1 | |
| SCHEMBL4508927 | 0.75 | NR1H2 (0.35) | — | |
| SCHEMBL4508780 | 0.74 | HSD11B1 (0.37) | L3MBTL1PTPN11POLBNR0B2ALDH1A1 | |
| SCHEMBL4513747 | 0.73 | MMP13 (0.38) | — | |
| SCHEMBL13674562 | 0.72 | KDM4E (0.36) | ALDH1A1 | |
| SCHEMBL2994583 | 0.71 | P2RX7 (0.36) | L3MBTL1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | L3MBTL1 3517/4885PTPN11 1035/4885POLB 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.